Showing results (691-700 of 978) with videos related to

Sort By:
Pageof 98
Molecular Immunology|September 22, 2009
L-ficolin (ficolin-2) insufficiency is associated with combined allergic and infectious respiratory disease in childrenMaciej Cedzynski, Anne P M Atkinson, Anna St Swierzko, et al.
Nature Communications|May 27, 2023
Deep learning enables satellite-based monitoring of large populations of terrestrial mammals across heterogeneous landscapeZijing Wu, Ce Zhang, Xiaowei Gu, et al.
Endocrinology|July 2, 2020
Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast CarcinomaSreeja Sreekumar, Kevin M Levine, Matthew J Sikora, et al.
Blood Advances|March 29, 2019
A scale for patient-reported symptom assessment for patients with Erdheim-Chester diseaseEli L Diamond, Anne S Reiner, Justin J Buthorn, et al.
Cancer Letters|June 24, 2019
Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinomaLan Cao, Ahmed Basudan, Matthew J Sikora, et al.
Molecular Immunology|March 25, 2009
Mannan-binding lectin-associated serine protease-2 (MASP-2) in a large cohort of neonates and its clinical associationsAnna St Swierzko, Maciej Cedzynski, Iwona Domzalska-Popadiuk, et al.
Journal of Occupational Rehabilitation|January 6, 2026
Effectiveness of Self-Help Interventions to Reduce Work Disability: A Rapid Mixed Methods Systematic ReviewM Atkinson-Graham, H Yu, L Cooper, et al.
Contemporary Clinical Trials|May 23, 2021
The Head and Neck Survivorship Tool (HN-STAR) Trial (WF-1805CD): A protocol for a cluster-randomized, hybrid effectiveness-implementation, pragmatic trial to improve the follow-up care of head and neck cancer survivorsTalya Salz, Jamie S Ostroff, Chandylen L Nightingale, et al.
Blood|May 13, 2020
Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemiaMelat T Gebru, Jennifer M Atkinson, Megan M Young, et al.
Health and Quality of Life Outcomes|February 20, 2016
Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Antonia V Bennett, Amylou C Dueck, Sandra A Mitchell, et al.
Pageof 98